Shares of Merck and Pfizer are way down from their previous peaks. Merck's lead drug, Keytruda, grew sales by 19% last year, but its era of patent-protected exclusivity is approaching its end.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

ANN ARBOR, MI - A longtime, iconic cheesesteak shop in Ann Arbor is officially for sale. Mr. Spots, 808 S. State St., has been on the market since late June and is currently listed for $1.2 ...

AUSTIN (KXAN) — Hays County began work Monday to widen a stretch of roadway within Wimberley, county officials announced. The construction project will widen RM 3237 at River Mountain Road and ...

The payment is triggered by the initiation, by Merck, of a Phase 2 clinical trial to evaluate the ... said Spyros Papapetropoulos, M.D., Ph.D., President and CEO of Neuphoria Therapeutics Inc. “This ...

Jadon Sancho and Antony will, alas, have to wait. 53) Raphael Varane (Como) Just an absolutely gutting end for a wonderful player. It wasn’t even particularly United’s fault that they never ...

During an R&D update yesterday Merck said it is hoping to claim eight new cardiovascular therapy approvals between now and 2030, for diseases like atherosclerosis, heart failure, pulmonary ...

mRNA-4157 is being tested in a 157-subject phase 2 alongside Merck's PD-1 checkpoint inhibitor Keytruda (pembrolizumab) as an adjuvant treatment after surgery for patients with melanoma who are at ...